Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the sale, the chief executive officer now directly owns 1,160,634 shares of the company's stock, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Ironwood Pharmaceuticals Trading Down 4.5 %

Shares of IRWD traded down $0.09 during trading hours on Friday, reaching $1.92. The stock had a trading volume of 2,151,349 shares, compared to its average volume of 2,572,680. The firm has a 50-day simple moving average of $3.54 and a 200 day simple moving average of $4.10. Ironwood Pharmaceuticals, Inc. has a 12 month low of $1.59 and a 12 month high of $15.65. The company has a market capitalization of $307.26 million, a price-to-earnings ratio of -64.00 and a beta of 0.29.

Analyst Upgrades and Downgrades

IRWD has been the topic of several research reports. StockNews.com downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, November 12th. Craig Hallum decreased their price objective on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Wednesday, January 22nd. Finally, JMP Securities dropped their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating on the stock in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Ironwood Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $10.67.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. KBC Group NV lifted its holdings in Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 3,198 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ironwood Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company's stock worth $150,000 after buying an additional 3,209 shares during the period. Creative Planning raised its position in shares of Ironwood Pharmaceuticals by 12.7% in the 3rd quarter. Creative Planning now owns 42,151 shares of the biotechnology company's stock worth $174,000 after acquiring an additional 4,749 shares in the last quarter. Quantinno Capital Management LP increased its holdings in shares of Ironwood Pharmaceuticals by 40.0% in the third quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company's stock valued at $79,000 after purchasing an additional 5,482 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Ironwood Pharmaceuticals by 2.2% in the fourth quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company's stock worth $1,252,000 after buying an additional 6,000 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.